Evaluation of matrix metalloproteinase-9 plasma levels in untreated new Relapsing–remitting multiple sclerosis patients and their first-degree family

Author(s):  
Mahsa Samangooei ◽  
Mojtaba Farjam ◽  
Zahra Niknam ◽  
Masoud Etemadifar ◽  
Mohammad hasan Meshkibaf ◽  
...  
2021 ◽  
pp. 1-9
Author(s):  
Leila Karimi ◽  
Nahid Eskandari ◽  
Vahid Shaygannejad

<b><i>Background:</i></b> We aimed to evaluate the therapeutic effects of interferon-beta (IFN-β) on hsa-miR29b-3p and hsa-miR326 in isolated T-helper (Th)1 and Th17 cells expressed by relapsing-remitting multiple sclerosis (RRMS) patients before and after 1 year of treatment with IFN-β. <b><i>Methods:</i></b> The study was done on 19 RRMS patients pre- and posttreatment with IFN-β to evaluate the frequency of Th1 and Th17 cells by flow cytometry. The expression level of hsa-miR-29b-3p and hsa-miR-326 in isolated Th1 and Th17 cells was assessed by quantitative polymerase chain reaction. Enzyme-linked immunosorbent assay was also used to measure the plasma levels of I interferon -gamma and interleukin (IL)-17A. <b><i>Results:</i></b> Th17 cells and plasma levels of IL-17A decreased in RRMS patients after IFN-β therapy but hsa-miR-29b-3p and hsa-miR-326 expression had no significant change in treated RRMS patients versus baseline. <i>MxA</i> gene expression was significantly induced upon IFN-β therapy in patients with RRMS. <b><i>Conclusion:</i></b> IFN-β therapy is more effective on Th17 than Th1, but it does not reform altered expression of hsa-miR-326 and hsa-miR-29b-3p in Th17 and Th1, respectively.


2010 ◽  
Vol 16 (4) ◽  
pp. 443-449 ◽  
Author(s):  
Mario HJ Vogt ◽  
Joop ten Kate ◽  
Roosmarie JM Drent ◽  
Chris H Polman ◽  
Raymond Hupperts

The pro-inflammatory cytokine osteopontin has been found to be highly expressed in multiple sclerosis lesions and plasma levels are increased during relapses in relapse-onset multiple sclerosis patients. The objective was to determine the relationship between osteopontin plasma and cerebrospinal fluid levels in relation to the immunoglobulin G index. In addition, osteopontin plasma levels were compared with osteopontin mRNA levels in peripheral blood mononuclear cells and bone-specific markers to analyse whether osteopontin may be peripherally produced. Osteopontin and bone-specific markers were determined in paired plasma—cerebrospinal fluid samples and serum samples of relapse-onset multiple sclerosis patients ( n = 36), respectively. Osteopontin mRNA levels were determined by quantitative polymerase chain reaction analysis. Compared to healthy controls ( n = 20), plasma osteopontin levels were significantly increased in relapsing-remitting multiple sclerosis patients and correlated ( r = 0.43, p = 0.013) with the immunoglobulin G index. In contrast, cerebrospinal fluid osteopontin levels correlated neither with plasma osteopontin in paired samples nor with the immunoglobulin G index. Since osteopontin mRNA levels in peripheral blood mononuclear cells of relapsing-remitting multiple sclerosis patients did not correlate with osteopontin plasma levels, peripheral blood mononuclear cells might not be the major source for the increased osteopontin plasma levels. Osteopontin plasma levels correlated ( r = 0.42, p = 0.035) with the bone-specific degradation product C-telopeptide of type-1 collagen. In addition, another immunomodulatory molecule involved in bone metabolism, 25-OH vitamin D, correlated negatively ( r = —0.359, p = 0.048) with the immunoglobulin G index. This study suggests that bone-related molecules like osteopontin and vitamin D with important immunomodulatory functions are related to the immunoglobulin G index in relapsing-remitting multiple sclerosis patients.


Sign in / Sign up

Export Citation Format

Share Document